We chase the miracles of science of science to improve people's lives. But we cannot do it alone. We work closely with healthcare professionals, patient associations, institutions and other companies in order to make a change in patients' lives.
Our areas of expertise range from immunological and inflammatory diseases to cardiovascular diseases, from diabetes to rare diseases, from neurology to onco-haematology, from prevention through immunisation and vaccines to self-medication solutions.
Immunology and inflammation
After making available the first advanced best-in-class biological therapy for atopic dermatitis, Sanofi has pushed the boundaries of science a little further by providing answers for many other chronic inflammatory conditions triggered by type 2 inflammation, such as asthma, chronic rhinosinusitis with nasal polyposis, prurigo nodularis and eosinophilic oesophagitis. Its robust pipeline also includes potential treatments for other dermatological, respiratory and gastrointestinal chronic immunological and inflammatory conditions. For more information visit :
Neurology
Using cutting-edge technologies, Sanofi is developing targeted therapies to modify the course of certain neurodegenerative diseases, including multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS). The aim is to identify and develop best-in-class drugs in this field, capable of slowing or stopping neurodegeneration, controlling neuroinflammation, and protecting or even repairing lesions in the central nervous system.
Rare diseases
Over the course of 40 years, Sanofi has made available the first enzyme replacement therapies for the treatment of a number of rare lysosomal storage diseases (Gaucher disease, Anderson-Fabry disease, Pompe disease and Mucopolysaccharidosis I), recently joined by the first specific therapy for acid sphingomyelinase deficiency or ASMD (for more information, visit www.malattielisosomiali.it).
Even when a treatment has proven effective, Sanofi continues its commitment to research to improve standards of care. It has also made available two support programmes for patients and caregivers:
- the TUTOR programme, dedicated to people undergoing treatment with enzyme replacement therapies. For information contact: 800 893 412
- the HERE FOR YOU programme, designed for people being treated with oral therapy for Gaucher disease.
For information contact: 800 036480
Rare blood disorders
Rare haematological diseases represent one of the areas where patients' greatest unmet needs persist. In this area, Sanofi has provided the first treatment for acquired thrombotic thrombocytopenic purpura (aTTP) (learn more at www.capirelattp.it) and is developing therapies for cold agglutinin disease (CAD), a rare type of autoimmune haemolytic anaemia, and other rare blood clotting disorders.
Oncology and haematology
Sanofi is committed to significantly improving the health and quality of life of people with oncological diseases and blood cancers, with a particular focus on multiple myeloma, a disease that still represents a considerable therapeutic challenge.
Vaccines
We believe in a world where no one has to suffer or die from vaccine-preventable diseases.
Globally, Sanofi invests €500 million each year in research and development, enabling the vaccination of more than 500 million people worldwide, with 2.5 million doses of vaccines provided, every day.
Sanofi works with institutions, health authorities, and the medical and scientific communities to improve access and increase vaccine coverage to achieve public health goals. An ongoing commitment that is also reflected in the study, production and distribution of immunization solutions, devoted to improving the health and well-being of the population at every stage of life.
For more information visit: www.missioneprevenzione.it
Diabetes and cardiovascular diseases
Combining tradition and innovation:
this is the goal of Sanofi, which for more than thirty years
has been on the front line alongside patients at high cardiovascular risk - thanks to the first cholesterol-lowering monoclonal antibody of the new class of Pcsk9 inhibitors in development - with hypertension and at risk of thromboembolic events. Sanofi is at the side of people with diabetes following an integrated approach, customised to patients' needs and with a broad spectrum of cutting-edge therapeutic solutions, with an eye to the future and to the prevention of type 1 diabetes, thanks to the advent of immuno-diabetology.
Consumer Healthcare
Health in Your Hands
At Sanofi Consumer Healthcare, we are committed to building a healthier future by helping people help themselves. We provide self-medication solutions to better manage personal well-being and promote a culture of responsible self-care, for ourselves, our communities and our planet. We do this through consumer-inspired and science-based products and solutions.